De Luca G, Verdoia M, Savonitto S, et al. - Among participants (n = 1,408) in the Elderly-ACS 2 trial (a randomized, open-label, blinded endpoint study), researchers determined the prognostic influence of body mass index (BMI) on the clinical results. In the Elderly-ACS 2 trial, low-dose (5 mg) prasugrel was compared with clopidogrel in elderly patients with acute coronary syndrome (ACS). Cardiovascular mortality was evaluated as the primary endpoint. Based on the median values of BMI, the groups of patients were defined (< or ≥ 25.7 kg/m²). A median follow-up of 367 days was performed. Findings revealed that the survival or the risk of major cardiovascular and bleeding complications were not conditioned by BMI in this elderly patient population with ACS. Experts reported consistent findings across various patient risk categories.